hotspot -WSS

hotspot

author：knowledge 2025-10-02 13:28:53 - browse：6

A pile of Zynex Medical batteries and electrode pads are seen at Michelle Bean's home — A pile of Zynex Medical batteries and electrode pads Kayana Szymczak for STAT

Sending patients heaps of medical supplies to score more money from insurers is common in the device industry. If insurers decline to cover the supplies, patients are stuck paying for materials they didn’t need.

STAT examined one of the companies perpetuating this practice, a pain management device company called Zynex Medical, and the frustration among both its patients and former employees. Here are five takeaways.

The ‘razor blade’ business model

Zynex sells nerve and muscle stimulation machines, known as TENS and EMS units, to treat pain and soothe muscles. But the company makes most of its money from monthly shipments of batteries and electrodes — almost 70% of its $184 million revenue in 2023 came from these supplies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Ethical issues complicate the benefits of medical crowdfunding

WSS

Ethical issues complicate the benefits of medical crowdfunding

Trump surgeon general acknowledges mistakes during Covid

Teach medical students about patients with intellectual disabilities

Ethical issues complicate the benefits of medical crowdfunding

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

focus

hotspot

The ‘razor blade’ business model

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

explore

The high cost of giving birth even with insurance

A new House health package & hospitals’ new site

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A new House health package & hospitals’ new site

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The (many) problems with a new study criticizing cancer screening

State Dept. review finds Biden bears some blame for Afghanistan failures

Congenital heart disease patients face new threat of heart failure

Walensky prepares to leave CDC — and Congress — behind

Illumina names Agilent executive as new CEO

leisure time

Humana sues Biden admin over Medicare Advantage audit rule

'Make People Better': The CRISPR babies story you probably don't know

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

In diabetes hearing, Sanders takes on a new foe: food makers

In diabetes hearing, Sanders takes on a new foe: food makers

hotspot

focus

hotspot

focus